Graham Simmons

15.5k total citations · 3 hit papers
132 papers, 10.0k citations indexed

About

Graham Simmons is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Virology. According to data from OpenAlex, Graham Simmons has authored 132 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Infectious Diseases, 37 papers in Public Health, Environmental and Occupational Health and 34 papers in Virology. Recurrent topics in Graham Simmons's work include Mosquito-borne diseases and control (37 papers), HIV Research and Treatment (34 papers) and SARS-CoV-2 and COVID-19 Research (33 papers). Graham Simmons is often cited by papers focused on Mosquito-borne diseases and control (37 papers), HIV Research and Treatment (34 papers) and SARS-CoV-2 and COVID-19 Research (33 papers). Graham Simmons collaborates with scholars based in United States, United Kingdom and Germany. Graham Simmons's co-authors include Paul Bates, Paul R. Clapham, Jacqueline D. Reeves, Stefan Pöhlmann, Andrew J. Rennekamp, Dhaval N. Gosalia, Scott L. Diamond, Timothy N. C. Wells, Amanda E. I. Proudfoot and Yanchen Zhou and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Graham Simmons

129 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

2005 804 citations Graham Simmons, Jacqueline D. Reeves et al. profile →
Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist

1997 508 citations Graham Simmons, Paul R. Clapham et al. Science profile →
Protease inhibitors targeting coronavirus and filovirus entry

2015 437 citations Yanchen Zhou, Kai Lü et al. profile →

Peers

Countries citing papers authored by Graham Simmons

Since Specialization

Citations

This map shows the geographic impact of Graham Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graham Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graham Simmons more than expected).

Fields of papers citing papers by Graham Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graham Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graham Simmons. The network helps show where Graham Simmons may publish in the future.

Co-authorship network of co-authors of Graham Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Graham Simmons. A scholar is included among the top collaborators of Graham Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graham Simmons. Graham Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spike and nucleocapsid antibody dynamics following SARS‐CoV‐2 infection and vaccination: Implications for sourcing COVID‐19 convalescent plasma from routinely collected blood donations 2024 ·Transfusion ·Clara Di Germanio, Xutao Deng, (unknown), Graham Simmons, (unknown), Eduard Grebe, Mars Stone, Bryan R. Spencer, Paula Saá, Elaine A. Yu, Marion C. Lanteri, Valerie Green, David J. Wright, (unknown), Steven Kleinman, Jefferson M. Jones, Brad J. Biggerstaff, Paul Contestable, Michael P. Busch	4
2	Comparative Evaluation of Select Serological Assays for Zika Virus Using Blinded Reference Panels 2024 ·Viruses ·Devy Emperador, Mars Stone, Eduard Grebe, Camille Escadafal, Honey Dave, Eve Lackritz, Cassandra Kelly‐Cirino, Ingrid B. Rabe, Diana P. Rojas, Michael P. Busch, Graham Simmons	0
3	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection 2022 ·Cell Reports ·Elizabeth McCarthy, Pamela M. Odorizzi, (unknown), (unknown), Iliana Tenvooren, Mars Stone, Graham Simmons, Peter W. Hunt, Margaret E. Feeney, Philip J. Norris, Michael P. Busch, Matthew H. Spitzer, Rachel L. Rutishauser	2
4	Vaccination of COVID ‐19 convalescent plasma donors increases binding and neutralizing antibodies against SARS‐CoV ‐2 variants 2022 ·Transfusion ·Clara Di Germanio, Graham Simmons, (unknown), (unknown), Mars Stone, Thomas J. Gniadek, Michael P. Busch	11
5	Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment 2022 ·Transfusion ·Anil Bagri, Rafael Ramiro de Assis, Cheng‐ting Tsai, Graham Simmons, (unknown), (unknown), Michelle Gatmaitan, Mars Stone, Clara Di Germanio, (unknown), (unknown), (unknown), Peter V. Robinson, Dawn C. Ward, Alyssa Ziman, David Seftel, Saahir Khan, Michael P. Busch, Philip L. Felgner, Laurence Corash	3
6	The Tetraspanin CD81 Is a Host Factor for Chikungunya Virus Replication 2022 ·mBio ·(unknown), (unknown), (unknown), (unknown), (unknown), Lars A. Carlson, Christine Goffinet, Graham Simmons, Wolfgang Baumgärtner, Gisa Gerold	14
7	SARS‐CoV ‐2 antibody persistence in COVID ‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance 2021 ·Transfusion ·Clara Di Germanio, Graham Simmons, Kathleen Kelly, (unknown), (unknown), (unknown), Mars Stone, (unknown), Eduard Grebe, Shuting Zhang, Peijun Ma, Marek Orzechowski, James Gomez, Jonathan Livny, Deborah T. Hung, Ralph R. Vassallo, Michael P. Busch, Larry J. Dumont	29
8	Selecting COVID ‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV ‐2 antibody assay 2021 ·Transfusion ·Erin Meyer, Graham Simmons, Eduard Grebe, (unknown), Sergej Franz, (unknown), Clara Di Germanio, Mars Stone, Paul Contestable, (unknown), Rita A. Reik, Ralph R. Vassallo, Pampee P. Young, Michael P. Busch, Phillip Williamson, Larry J. Dumont	12
9	Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants 2021 ·medRxiv ·Clara Di Germanio, Graham Simmons, (unknown), (unknown), Mars Stone, Thomas J. Gniadek, Michael P. Busch	2
10	An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope 2018 ·PLoS neglected tropical diseases ·Jing Jin, Michael B. Sherman, Daniel M. Chafets, (unknown), Kai Lü, Tzong‐Hae Lee, Lars A. Carlson, Marcus O. Muench, Graham Simmons	7
11	High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014 2016 ·Emerging infectious diseases ·Graham Simmons, Vanessa Brès, Kai Lü, Nathan M. Liss, Donald Brambilla, Kyle Ryff, Roberta Bruhn, (unknown), (unknown), Jeffrey M. Linnen, (unknown), Lyle R. Petersen, Phillip Williamson, Michael P. Busch	79
12	Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic 2016 ·The Journal of Infectious Diseases ·Michael P. Busch, Éster Cerdeira Sabino, Donald Brambilla, Maria Esther Lopes, Ligia Capuani, Dhuly Chowdhury, Christopher McClure, Jeffrey M. Linnen, Harry E. Prince, Graham Simmons, Tzong‐Hae Lee, Steven Kleinman, Brian Custer	48
13	Human keratinocytes restrict chikungunya virus replication at a post-fusion step 2014 ·Virology ·Éric Bernard, Rodolphe Hamel, Aymeric Neyret, Peeraya Ekchariyawat, Jean‐Pierre Molès, Graham Simmons, Nathalie Chazal, Philippe Desprès, Dorothée Missé, Laurence Briant	21
14	Filovirus Entry 2013 ·Advances in experimental medicine and biology ·Graham Simmons	16
15	No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected 2011 ·Science ·Konstance Knox, Donald R. Carrigan, Graham Simmons, Fernando Teque, Yanchen Zhou, John Hackett, Xiaoxing Qiu, Ka‐Cheung Luk, Gerald Schochetman, (unknown), Andreas M. Kogelnik, Jay A. Levy	87
16	Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein 2009 ·Virology ·Beatriz Salvador, Yanchen Zhou, Alain Michault, Marcus O. Muench, Graham Simmons	64
17	Comparison of CD4-independent infection by HIV-1, HIV-2 and SIV strains, and relevance of receptors other than CCR5 and CXCR4 for infection of primary cell types 2000 ·Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) ·Jacqueline D. Reeves, Graham Simmons, Nathalie Dejucq‐Rainsford, Sam Hibbitts, Áine McKnight, (unknown), José Moniz‐Pereira, Paul R. Clapham	1
18	CD4-Independent Infection by HIV-2 (ROD/B): Use of the 7-Transmembrane Receptors CXCR-4, CCR-3, and V28 for Entry 1997 ·Virology ·Jacqueline D. Reeves, Áine McKnight, (unknown), Graham Simmons, Patrick W. Gray, Christopher Power, Timothy N. C. Wells, Robin A. Weiss, Simon J. Talbot	123
19	Application of GPS 1994 ·Graham Simmons	4
20	Is CD4 sufficient for HIV entry? Cell surface molecules involved in HIV infection 1993 ·Philosophical Transactions of the Royal Society B Biological Sciences ·Paul R. Clapham, Áine McKnight, Graham Simmons, Robin A. Weiss	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact